FDA's Controversial Pregnancy Drug Decision, Explained

Health Affairs' Leslie Erdelack and Jessica Bylander discuss the
FDA's efforts to pull the pregnancy drug Makena from the market
and the implications for drug policy.


Join us in D.C. for an in-person happy hour event on November 17


Related Links:


FDA Panel Recommends Pulling Preterm Birth Drug From the
Market (New York Times)

Accelerated Approval of Cancer Drugs: No Economic Reward For
Drug Makers That Conduct Confirmatory Trials (Health Affairs)

Delays in Confirmatory Trials for Drug Applications Granted
FDA's Accelerated Approval Raise Concerns (Office of Inspector
General)

Podcast: Prescription Drug Policy, Drug Pricing & Aduhelm
With Rachel Sachs (Health Affairs This Week)



Currently, more than 70 percent of our content is freely
available — and we’d like to keep it that way. With your support,
we can continue to keep our digital publication Forefront and
podcasts free for everyone.


Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher |
Deezer | Overcast



Join us in D.C. for an in-person happy hour event on November 17